Covid-19 Study, Diagnostic and Therapeutic Transition

Da Yong Lu; Ting Ren Lu

doi:10.2174/2772434418666230331115936

Covid-19 Study, Diagnostic and Therapeutic Transition

Recent Adv Antiinfect Drug Discov. 2023 Mar 31. doi: 10.2174/2772434418666230331115936. Online ahead of print.

Authors

Da Yong Lu¹, Ting Ren Lu²

Affiliations

¹ School of Life Sciences, Shanghai University, Shanghai, 200444, China.
² College of Science, Shanghai University, Shanghai, 200444, China.

PMID: 36999700
DOI: 10.2174/2772434418666230331115936

Abstract

Introduction: The outbreak of coronavirus (severe acute respiratory syndrome coronavirus2, COVID-19, SARS-Co-2) in Wuhan, China occurred three years ago. However, the healthcare state and legislature for Covid-19 varied greatly worldwide.

Aims: After three years, the social life of most countries worldwide is gradually back to normal. Diagnosis and therapeutics worldwide are formalized now. Improvement of the knowledge about this devastating disease will shed new light on its management and spawn the development of new counter measures. Due to the differences in socioeconomic conditions and policies worldwide, the diagnostic and therapeutic transition should be established.

Methods: The schedules and techniques of vaccines, drugs, or other therapeutic strategies could be formalized in the future. The origin and hidden nature of Covid-19 biology (relationship between viral strain and drug targeting) should be further investigated. Knowledge and opinion breakthroughs may significantly heighten the quality of preventive and therapeutic strategies against Covid-19.

Results: To further stabilize the global situation, the issues of viral spread and induced mortality should be emphasized. Existing animal models, pathophysiological knowledge, and therapeutics for different infected patients played vital roles. The diagnostic widening, variants of COVID, and therapeutic selection worldwide totally solve the complex outcomes and promote the curability for infected patients.

Discussion: Different diagnostic platforms can reach different therapeutic selections, responses, and benefits in the clinic. It will provide advanced diagnostic dimensions, therapeutic paradigms, and drug selection strategies for the purpose of the greatest benefiting and recoveries of Covid-19 patients.

Conclusion: To speed up the global fight against Covid-19, biomedical knowledge, prophylactic vaccines, and therapeutic paradigms should be updated in dynamic states.

Keywords: Clinical trial; Covid-19; Drug development; Infection targets; Viral infection; Viral pathology; Viral prevention.